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Cationic antimicrobial peptides (CAMPs) are important actors in host innate immunity and represent a
promising alternative to combat antibiotic resistance. Here, the bactericidal activity of two CAMPs (LL-37
and CAMA) was evaluated against Pseudomonas aeruginosa (PA) in the presence of IB3-1 cells, a cell line
derived from patients with cystic ﬁbrosis. The two CAMPs exerted different effects on PA survival
depending on the timing of their administration. We observed a greater bactericidal effect when IB31 cells were pretreated with sub-minimum bactericidal concentrations (Sub-MBCs) of the CAMPs prior to
infection. These ﬁndings suggest that CAMPs induce the production of factors by IB3-1 cells that improve
their bactericidal action. However, we observed no bactericidal effect when supra-minimum bactericidal
concentrations (Supra-MBCs) of the CAMPs were added to IB3-1 cells at the same time or after infection.
Western-blot analysis showed a large decrease in LL-37 levels in supernatants of infected IB3-1 cells and
an increase in LL-37 binding to these cells after LL-37 administration. LL-37 induced a weak inﬂammatory
response in the cells without being toxic. In conclusion, our ﬁndings suggest a potential prophylactic
action of CAMPs. The bactericidal effects were low when the CAMPs were added after cell infection, likely
due to degradation of CAMPs by bacterial or epithelial cell proteases and/or due to adherence of CAMPs
to cells becoming less available for direct bacterial killing.
© 2022 The Authors. Published by Elsevier Masson SAS on behalf of Institut Pasteur. This is an open
access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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While the search for alternatives to antibiotics is becoming
increasingly important [1,2], cationic antimicrobial peptides
(CAMPs) are gaining attention as potential therapeutic agents [3].
CAMPs are an extremely diverse group of low molecular weight
natural peptides that form part of the ﬁrst line of the innate immune defense of most living organisms, ranging from insects to
plants to animals, including humans [4]. As effectors of innate
immunity, CAMPs exhibit rapid action and a broad spectrum of
activity against both Gram-positive and Gram-negative bacteria,
fungi, viruses, and parasites, independently from their resistance
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proﬁles [5,6]. These peptides act as effective modulators of
inﬂammation, including angiogenesis, cytokine production,
chemotactic functions, modulation of immune cell differentiation,
and the initiation of adaptive immunity [7]. The CAMP LL-37 is a
member of the cathelicidins obtained by extracellular cleavage with
proteinase-3 of the C-terminal part of the only human cathelicidin
identiﬁed to date called human cationic antimicrobial protein
(hCAP18) [6,8]. LL-37 is produced by many human cell types, such
myeloid cells, neutrophils, epithelial cells, mast cells, monocytes,
and keratinocytes. Epithelial cells of the respiratory tracts represent
a major source of this peptide [5,9]. The production of this 37 amino
acid peptide is induced by inﬂammatory or infectious stimuli and
has antimicrobial activity against both Gram-positive and Gramnegative bacteria. It has a net positive charge of þ6 at a physiological pH and exerts its direct antibacterial activity by either disrupting bacterial membranes adopting a toroidal-pore model [10],
or interfering with intracellular processes following to

https://doi.org/10.1016/j.micinf.2021.104928
1286-4579/© 2022 The Authors. Published by Elsevier Masson SAS on behalf of Institut Pasteur. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).
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multiplicity of infection
optical density
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alkaline protease
phosphate-buffered saline
polyvinylidene diﬂuoride
Pseudomonas aeruginosa elastase
prostaglandin E2
phenylmethylsulfonyl ﬂuoride
Roswell park memorial institute
sodium dodecyl sulfate-polyacrylamide gel
electrophoresis
SD
standard deviation
SPSS
statistical package software for social science
Sub-MBCs sub-minimum bactericidal concentrations
Supra-MBCs supra-minimum bactericidal concentrations
TNF-a
tumor necrosis factor-a
TBS-Tween tris-buffered saline-Tween
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cationic antimicrobial peptides
CF
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cystic ﬁbrosis transmembrane conductance regulator
CFU
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Cytotoxicity % percentage cytotoxicity
DMEM
Dulbecco’s modiﬁed Eagle’s medium
ECCMID European congress of clinical microbiology and
infectious diseases
ELISA
enzyme-linked immunosorbent assay
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fetal bovine serum
hCAP18
human cationic antimicrobial protein
HLEC
human lung epithelial cell line
IL
interleukin
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lactate dehydrogenase
LPS
lipopolysaccharide
MBC
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antibiotics by mutating and the presence of abnormal amounts of
bronchial mucus, which is a favorable niche for bacterial proliferation [18].
Traditionally, examination of the bactericidal effects of CAMPs
has been performed in host cell-free media. Bactericidal activities of
four CAMPs against clinical and laboratory strains of Staphylococcus
aureus, Streptococcus pneumoniae, and PA, either antibiotic susceptible or multidrug-resistant has been published by our team
previously [19]. Among the tested peptides, LL-37 and CAMA
showed the most potent bactericidal activities against PA, therefore
these two peptides were selected in the present work for further
experimental studies in presence of human lung epithelial cell lines
(HLECs) to reﬂect the natural conditions of host infections. We
investigated the bactericidal activity of LL-37 and CAMA at three
different timepoints (30 min pre-infection, at the same time as
infection, and 30 min post-infection). Western-blot experiments
were also performed to evaluate the stability of LL-37 when added
to human cells infected with PA. The cytotoxicity and immunomodulatory effects of LL-37 and CAMA were assessed on two
HLECs.
Part of this work was presented orally at the European congress
of clinical microbiology and infectious diseases (ECCMID) 2019 in
Amsterdam, Holland (April 13e16, presentation number O0424).

translocation. Furthermore, LL-37 neutralizes the activity of bacterial lipopolysaccharide (LPS). Besides its direct antimicrobial activity, LL-37 can modulate inﬂammation; it is chemotactic for
neutrophils, monocytes, mast cells and T cells, induces degranulation of mast cells, affects transcriptional responses in macrophages,
and maintains a balance between pro- and anti-inﬂammatory
mediators, helping in combating the infection and limiting the inﬂammatory response to prevent damage to the host [6,11]. Moreover, LL-37 promotes wound vascularization and angiogenesis, and
they have also been implicated in anti-cancer activities [11].
The CAMP CAMA is a synthetized cecropin-melittin 15 amino
acid hybrid peptide, composed of N-terminal alpha-helical segment
of cecropin A(amino acid 1e7) and melittin A(2e9). It is a novel
small peptide with a net positive charge of þ8 at a physiological pH
that exerts a potent antibacterial and synergistic activity by disrupting bacterial outer membrane through forming ion-permeable
channels in toroidal-pore and carpet-like models [12]. Cecropins
were originally isolated from the hemolymph of a North American
silk moth, Hyalophora cecropia [13], while melittin was isolated
from honey bee [6].
The lung is the most exposed organ to microbes and lung infections are a major cause of death from infection worldwide.
Opportunistic bacteria such as Pseudomonas aeruginosa (PA) are an
important cause of lung infections in immunocompromised or
critically ill patients [14]. PA is a ubiquitous organism that persists
in both community and hospital settings due to its ability to survive
on minimal nutritional requirements and tolerate a variety of
physical conditions [15]. Patients with disrupted lung immunity or
mucosal clearance, such as those with cystic ﬁbrosis (CF), acquire
bacterial infections that typically do not resolve, even with antibiotic treatment [14]. CF is a well-characterized, lethal, autosomal,
recessive inherited disorder found predominantly in Caucasians
due to mutations in the cystic ﬁbrosis transmembrane conductance
regulator (CFTR) gene, characterized by chronic lung bacterial infections. Such infections are the main cause of morbidity and
mortality of CF patients. The major colonizing pathogen for people
with CF is arguably PA [16,17]. PA lung infections resist the host
response, as well as antibiotic treatment used to eradicate the
microorganism from the lungs. The persistence of infection in CF
airways is partially due to the ability of PA to develop resistance to

2. Materials and methods
2.1. CAMPs
LL-37 human cathelicidin (LLGDFFRKSKEKIGKEFKRIVQRIKD
FLRNLVPRTES) at 96,7% purity and CAMA cecropin(1e7)-melittin
A(2e9) (KWKLFKKIGAVLKVL) at > 95% were purchased from
Bachem AG (Bubendorf, Switzerland). The synthetic peptides were
dissolved in sterile water at a concentration of 2560 mg/mL and then
aliquoted and stocked at 20  C before use. Diluted solutions were
prepared on the day of use.
2.2. Cell lines and culture conditions
HLECs used in this study consisted of the human bronchial
epithelial IB3-1 and human adenocarcinoma alveolar epithelial
2
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absence of IB3-1 cells. A control well without drugs was used for
each condition.

A549 cell lines. Both cell lines were purchased from the American
type culture collection (ATCC). IB3-1 cells, derived from a CF patient
with a DF508/W1282X mutant genotype and immortalized using
adeno12/SV40, were grown in LHC-8 medium (Gibco) supplemented with 10% fetal bovine serum (FBS) (SigmaeAldrich), 100
units/mL penicillin and 0.1 mg/mL streptomycin (Gibco), 1 mM
HEPES buffer (SigmaeAldrich), and 2 mM L-glutamine (Gibco) at
37  C/5% CO2. A549 cells were cultured in Dulbecco's modiﬁed
Eagle's medium (DMEM) with Glutamax (Gibco) supplemented
with 10% FBS, 100 units/mL penicillin and 0.1 mg/mL streptomycin
at 37  C/5% CO2.

2.5. Assessment of LL-37 stability in IB3-1 cultures infected with
PAK
IB3-1 cells were incubated with PAK for 30 min at a MOI of 1 and
then supernatants were harvested, centrifuged to remove bacteria
and non-adherent cells and stored at 20  C until use. Later, after
their thawing, these cell-free supernatants were incubated with
exogenously added LL-37 at 1 mg/mL ﬁnal concentration. This
approach allows preventing any interaction between LL-37 and
IB3-1 cells and/or PAK. In a second approach, LL-37 was directly
added to the culture plates, allowing interaction with both IB31 cells and/or PAK. Cells extracts from IB3-1 cultures, infected or not
with PAK at MOI 5 were analyzed. Furthermore, Western-blot
analysis was also performed on cell extracts from IB3-1 cultures
stimulated with vitamin D (SigmaeAldrich) at a ﬁnal concentration
of 100 nM for 24 h. Vitamin D is known to up-regulate LL-37
expression by host cells. THP 1 cells were used as a positive control
for LL-37 expression. THP 1 is a human monocytic cell line derived
from an acute monocytic leukemia patient that were purchased
from the ATCC and cultured in Roswell Park Memorial Institute
(RPMI) 1640 medium (Bio-Rad). In certain experiments, cell-free
supernatants from IB3-1, infected or not, were thawed and pretreated with the serine protease inhibitor phenylmethylsulfonyl
ﬂuoride (PMSF, SigmaeAldrich) at 2 mM ﬁnal concentration for
30 min, before addition of LL-37.
Kinetic analyses at 37  C were carried out for the two approaches. A 10 mL sample was removed at various timepoints (0.5, 1,
2, and 6 h) and stored at 20  C until analysis. The stability of LL-37
in the supernatants was determined by assessing the level of
exogenous LL-37 by western-blotting for the indicated time points
under the different conditions (LHC-8, PAK, IB3-1, and IB3-1þPAK).
In the second approach, LL-37 levels in the cell pellets were also
determined to detect any interaction between LL-37 and IB3-1 cells
at the indicated timepoints (0.5, 1, 2, and 6 h) and under same
conditions (LHC-8, PAK, IB3-1, and IB3-1þPAK).

2.3. Bacteria and growth conditions
The wildtype PA strain (PAK) was purchased from the ATCC
(strain ATCC 53308). A single bacterial colony from an overnight
culture on Luria Bertani (LB) agar plates was grown overnight with
shaking in 20 mL LB medium at 37  C. The obtained bacterial suspension was further diluted in fresh LB and grown again for 4 h to
achieve mid-log phase. After centrifugation at 3000g at 4  C for
15 min, the bacterial pellet was rinsed and suspended in an
appropriate volume of phosphate-buffered saline (PBS). The bacterial concentrations were calculated according to the optical
density (OD) value measured at 600 nm and further adjusted to the
approximate desired concentration for in vitro bacterial infection
experiments [20].
2.4. Infection of IB3-1 cultures with PAK and treatment with CAMPs
Infection experiments were performed to evaluate the bactericidal activity of the two peptides (LL-37 and CAMA) against PAK in
the presence of IB3-1 cells. Two concentrations of each peptide
were used, one lower and one higher than the minimal bactericidal
concentration (MBC) of each peptide against PAK, designated subminimum bactericidal concentration (sub-MBC) and supraminimum bactericidal concentration (supra-MBC), respectively.
The MBC for each peptide was deﬁned by ﬁrst determining the
minimal inhibitory concentration (MIC) values of LL-37 and CAMA
against PAK by microbroth dilution, as described previously [21,22].
The MBC for each peptide was further deﬁned by plating the contents of the ﬁrst three wells showing no visible growth of bacteria
onto Mueller Hinton Agar (MHA) plates, followed by incubation for
24 h [19,23]. The MIC is deﬁned as the lowest concentration of an
antimicrobial agent that prevents visible growth of a microorganism in an agar or broth dilution susceptibility test. Whereas the
MBC is the lowest concentration of an antimicrobial agent that kills
99.9% of a particular organism [19]. Cell infections were performed
in serum-free culture medium. IB3-1 cells were seeded in 12-well
plates (TPP® tissue culture plates) and grown until conﬂuence.
Two hours before infection, culture medium was aspired from wells
and a serum-free medium without antibiotics was gently added.
Thirty minutes before infection, cells were counted using the trypan blue exclusion test of cell viability (Gibco) and stimulated with
PAK at a multiplicity of infection (MOI) of 1. The CAMPs were added
30 min pre-infection, at the same time as infection, or 30 min postinfection. The plates were centrifuged at 80g at 37  C for 5 min
and incubated at 37  C/5% CO2 to initiate infection and ensure
similar contact between the mammalian cells and bacteria [20].
After 2 h of incubation, the wells were scraped and the cells homogenized gently and repeatedly with pipetting to guarantee
obtaining all intra- and extra-cellular bacteria. Serial dilutions were
plated onto LB agar plates and the plates incubated for 24 h at 37  C.
The bactericidal effect of LL-37 and CAMA was measured by
counting bacterial colonies on the plates and expressing the value
as colony-forming units (CFUs) relative to that of treatment in the

2.5.1. Western-blotting analyses
Cell lysates were prepared using 1X RIPA at pH 7.4 (Bio Basic, NY,
USA). Proteins samples were diluted in LHC-8 medium with 4X
Laemmli buffer (Bio-Rad) containing b-mercaptoethanol and
loaded onto a 15% acrylamide gel and separated for 1e2 h at 130 V.
The proteins were then transferred to a polyvinylidene diﬂuoride
(PDVF) membrane using an IBlot 2 type device (Invitrogen) and
nonspeciﬁc binding sites were blocked with 5% milk in trisbuffered saline-Tween (TBS-Tween) buffer for 1 h. The membrane
was then washed with TBS-Tween and subsequently incubated
overnight with the primary anti-human antibody CAP18 (diluted
1:1000, Hycult Biotech) at 4  C under shaking. The next day, the
membrane was washed and incubated in the secondary anti-mouse
IgG (antibody diluted 1:5000, Cell Signaling Technology) for 1 h at
room temperature. The developer solution, containing equal volumes of the two reagents, was placed on the membrane for 5 min in
the dark. All blots were imaged with ultraviolet rays using an LAS3000 device.
2.6. Stimulation of HLECs with various CAMPs for cytotoxicity and
immunological assays
HLECs were seeded in 12-well plates and cultured for one day to
obtain a concentration of 1.6  106 cells/mL (1 mL per well). Before
treatment, supernatants were removed, 1 mL serum-free medium
was added to each well, and the cells allowed to rest for 1 h [24].
3
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Subsequently, HLECs were stimulated with LL-37 (5, 10, 15, 25, 50,
and 65 mg/mL) and CAMA (0.5, 5, 10, 15, 25, and 35 mg/mL) for 24 or
48 h. These concentrations were tested after showing potent
bactericidal activity against PA [19].
Cell lysis due to treatment of the HLECs with various concentrations of CAMPs for 24 or 48 h was determined in vitro using the
Lactate dehydrogenase (LDH)-based CytoTox 96®Non-Radioactive
Cytotoxicity Assay according to the manufacturer's instructions
(Promega). After the desired incubation time, supernatants were
aliquoted, centrifuged at 400g at 4  C for 5 min to obtain cell-free
samples, and the samples immediately analyzed for LDH. The dynamic range of the assay was determined using LDH released from
non-treated cells as a negative control and LDH released from cells
lysed with Triton X-100 as a control for maximum release. The
average background values of the culture medium were subtracted
from all values of the experimental wells. The corrected values
were used in the following formula recommended by the manufacturer to compute the percentage cytotoxicity (cytotoxicity %):

CAMA. Overall, there was only marginal bactericidal activity of subMBCs of LL-37 and CAMA against PAK at all three timepoints
(30 min pre-infection, same time as infection, and 30 min postinfection) in the absence of IB3-1 cells (P > 0.05 for all conditions,
except for LL-37 30 min pre-infection) (Fig. 1A and B). However, in
the presence of IB3-1 cells, the sub-MBCs of LL-37 and CAMA were
able to signiﬁcantly eliminate PAK organisms when added 30 min
pre-infection (P ¼ 0.003 for LL-37 and P ¼ 0.047 for CAMA). Such a
reduction in bacterial viability at sub-MBCs in the presence of IB31 cells was more signiﬁcant than in their absence (Fig. 1A and B)
(P ¼ 0 for both LL-37 and CAMA). Indeed, in the presence of IB31 cells, sub-MBCs of LL-37 and CAMA were able to kill 83.5% and
99% of PAK, respectively. In their absence, these concentrations
killed only 60.5% and 53%, respectively. However, the sub-MBCs of
the tested peptides were ineffective if added at the same time as
infection of the mammalian cells or 30 min post-infection (P > 0.05)
(Fig. 1 A and B).

Cytotoxicity % ¼ 100*experimental LDH release (OD490)/
maximum LDH release (OD490)

3.2. Decrease in the efﬁcacy of LL-37 and CAMA when
administrated at the same time as infection or 30 min post-infection
of IB3-1 cells

The treatment was considered to not be cytotoxic for
values < 10% [25].
The concentrations of interleukin (IL)-6, IL-8, and prostaglandin
E2 (PGE2) in the supernatants were measured using a capture
enzyme-linked immunosorbent assay (ELISA) following the manufacturer's suggestions (R&D Systems, Inc). After the desired time
of incubation, the tissue culture supernatants were aliquoted,
centrifuged at 3500g at 4  C for 5 min to obtain cell-free samples,
and stored at 20  C before assaying the cytokines.

In the absence of IB3-1 cells, LL-37 and CAMA exhibited total
killing against PAK at the supra-MBC (50 mg/mL for LL-37 and 5 mg/
mL for CAMA) at all three timepoints (30 min pre-infection, same
time as infection, and 30 min post-infection) (P < 0.05) (Fig. 1A and
B). However, in the presence of IB3-1 cells, supra-MBCs of LL-37 and
CAMA were less effective if added at the same time as infection or
post-infection, killing only 53.5% and 72.8% of PAK, respectively.
Furthermore, addition of the supra-MBCs of these two peptides
30 min post-infection in the presence of IB3-1 cells appeared to be
ineffective, showing no killing of PAK (P > 0.05) (Fig. 1A and B).

2.7. Statistical analyses
All experiments were performed in at least three independent
assays. The results are expressed as the mean ± standard deviation
(SD) of the three independent assays and the data were analyzed
using a general linear model procedure of statistical package software for social science (SPSS, version 20.00, SPSS Institute Inc.,
Chicago, IL, USA). The Shapiro Wilk test was used to evaluate the
normality of the variables. Variance analyses followed by multiple
comparisons were used to assess the efﬁcacy of the CAMPs under
all conditions. KruskaleWallis tests followed by ManneWhitney
tests were used to evaluate differences in cytotoxicity, and IL-6,
IL-8, and PGE2 levels relative to the control. P values  0.05 were
considered statistically signiﬁcant. Bands from the Western-blot
experiments were quantiﬁed using Fiji software (Schindelin, J;
Arganda-Carreras, I. & Frize, E. et al. (2012)). GraphPad Prism 7
software was used for ANOVA-type statistical tests. P values < 0.01
were considered statistically signiﬁcant.

3.3. Decrease in exogenous LL-37 levels in the supernatants of
infected IB3-1 cells
Our results led us to postulate that LL-37 is likely degraded by
proteases produced by IB3-1 cells upon their infection by PAK or
that this peptide is sequestrated by IB3-1 cells and then becomes
less available to kill the bacteria. The hypothesis stating that LL-37
is degraded by IB3-1 cells was tested by incubating the peptide
with supernatants obtained from IB3-1 cells infected with PAK for
0.5, 1, 2, and 6 h under various conditions (LHC-8, PAK, IB3-1, and
IB3-1þPAK), followed by Western-blot analysis of the supernatants.
The bands observed in LHC-8 medium or in the presence of PAK
alone were identical for all timepoints, showing that LL-37 was
stable for up to 6 h under these conditions (Fig. 2A). However, the
intensity of the LL-37 band in supernatants from uninfected IB31 cells decreased in a time-dependent manner, suggesting possible
degradation. Degradation of LL-37 appeared to be even greater
when it was incubated with supernatants from PAK infected IB31 cells. Indeed, LL-37 was no longer visible by Western-blotting
after 6 h of incubation with supernatants of IB3-1 cells infected
with PAK (Fig. 2A). Quantiﬁcation of the Western-blots performed
in triplicate from three independent samples under identical conditions showed a 28% decrease in LL-37 levels between 0.5 and 6 h
when it was incubated with supernatants from uninfected IB31 cells, which reached 49% when it was incubated with supernatants from IB3-1 cells infected with PAK (P < 0.01) (Fig. 2 B).
When supernatants from IB3-1 cells were pretreated with the
serine-protease inhibitor PMSF, no changes were observed in the
magnitude of LL-37 degradation by these supernatants (Fig. 1 of the
supplementary data).

3. Results
3.1. Prophylactic effect of Sub-MBCs of LL-37 and CAMA against PAK
We ﬁrst examined the efﬁcacy of the CAMPs in the presence of
IB3-1 cells. The killing potency of LL-37 and CAMA against PAK in
the presence or absence of IB3-1 cells was determined at two
different concentrations of each CAMP administrated at three
different times. The MBC values for LL-37 and CAMA against PAK
were 32 and 4 mg/mL, respectively [19]. Thus, the tested sub-MBCs
(the concentration of an antimicrobial agent that is lower than its
MBC) were 25 mg/mL for LL-37 and 2.5 mg/mL for CAMA and the
Supra-MBCs (the concentration of an antimicrobial agent that is
higher than its MBC) were 50 mg/mL for LL-37 and 5 mg/mL for
4
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Fig. 1. Bactericidal effects of A. LL-37 and B. CAMA against PAK in the presence or absence of HLECs at three different timepoints of CAMP administration. Bar graphs show the
means ± SD from three independent experiments of PAK survival expressed as colony forming units (CFU). *P < 0.05 for treated vs untreated controls.

Fig. 2. Western-blot analysis of the stability of exogenously added LL-37 to IB3-1 supernatants. A. This panel shows the evolution of the levels of LL-37 added to IB3-1 supernatants
in different conditions. B. Semi-quantiﬁcation showing LL-37 levels (percentages). Data are expressed as the percentage of remaining LL-37 in the various conditions compared to
those of LL-37 levels in LHC-8 culture medium; mean ± SEM; n ¼ 3 separate experiments. *P < 0.01 for supernatants versus culture medium.

to bind to IB3-1 cells with high afﬁnity (in both uninfected and
infected IB3-1 cells).
To address whether IB3-1 cells produce LL-37 during infection
by PAK and whether this endogenous LL-37 interfere with the
quantiﬁcation of the exogenously added LL-37, Western-blot B
analysis was performed. The results showed that LL-37 is not
upregulated by this bacterium (Fig. 2A of the supplementary data).
Furthermore, Western-blot analysis performed on cell extracts
from IB3-1 cultures stimulated with vitamin D showed that these
cells do not produce LL-37. Thus, IB3-1 cells are not able to synthesize LL-37 and the variations observed in the levels of LL-37

3.4. Increase of LL-37 quantity in IB3-1 cell pellets
We examined whether a portion of the exogenously added LL37 was able to bind to IB3-1 cells by carrying out Western-blots
on IB3-1 cell pellets under two culture conditions (IB3-1 and IB31þPAK) after incubations of 0.5, 1, 2, and 6 h. We observed a
time-dependent increase in the intensity of the LL-37 bands for
samples from both uninfected and infected IB3-1 cells (Fig. 3A).
Quantiﬁcation of the protein bands showed an increase of
approximately 95% in the amount of cell-associated LL-37 between
0.5 and 6 h under the two conditions (Fig. 3B). Thus, LL-37 appears
5
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Fig. 3. Western-blot analysis of the binding of exogenously added LL-37 to IB3-1 pellets. A. Representation of LL-37 and b-actin in absence and presence of PAK. B. Semiquantiﬁcation, showing LL-37 levels present in the pellets normalized to that of b-actin. Data are expressed as percentages; mean ± SEM; n ¼ 3 separate experiments.

We obtained different results with the A549 cell line. A549 cells
released neither IL-6 nor IL-8 following treatment with either LL-37
or CAMA (Fig. 5B). However, both peptides induced PGE2 release
from A549 cells in a time and dose-dependent manner, but it was
not statistically signiﬁcant (P > 0.05).

associated to IB3-1 cell pellets are not due to an interference with
endogenous LL-37 (Fig. 2B of the supplementary data).
3.5. No cytotoxic effect of CAMPs on HLECs after up to 48 h of
treatment
We screened the two CAMPs (LL-37 and CAMA) for their cytotoxicity based on LDH release from the cytosol of two HLECs cell
lines, IB3-1 and A549, 24 and 48 h post-treatment. LDH release was
<5% for all tested conditions for both CAMPs and both cell lines
(Fig. 4AeC). Thus, treatment with LL-37 and CAMA up to 50 and
35 mg/mL, respectively, had no cytotoxic effect on either the IB3-1
or A549 cell lines 24 and 48 h post-treatment.

4. Discussion
The role of CAMPs in the mechanism of killing various bacteria
has been extensively explored [26], but mostly in the absence of
host cells [12,27]. However, host cells can potentially inﬂuence the
bactericidal actions of CAMPs, thus introducing an important bias
in the interpretation of the actual role of these peptides. Going
beyond such studies, we investigated the bactericidal activity of LL37 and CAMA against PAK, a laboratory strain of PA, in the presence
of the bronchial epithelial cell line, IB3-1, derived from CF patients.
Bronchial epithelial cells are the ﬁrst target of bacteria, such as PA,
that colonize patient airways [17]. Our results show that sub-MBCs
of LL-37 and CAMA kill PAK more effectively when added to IB31 cells 30 min pre-infection than when added at the same time or
30 min post-infection. These ﬁndings suggest a possible interaction
between CAMPs and IB3-1 cells, resulting in an enhanced bactericidal effect. Such improved bactericidal activity occurred at levels
that are well within the range of the sub-MBCs. Thus, the effect of
these two peptides against PAK appears to be indirect (host cellmediated) via a mechanism that is yet to be precisely identiﬁed.
It is well known that numerous CAMPs are able to bind to cellular
receptors, inducing a variety of receptor-mediated functions [28],
such as the stimulation of angiogenesis, cutaneous wound healing,
and chemoattraction of inﬂammatory and immune cells [29]. Thus,
it is conceivable that CAMPs can stimulate IB3-1 cells to produce
factors that enhance the bactericidal effects of these peptides.
However, LL-37 and CAMA showed much less bactericidal activity
when added to IB3-1 cells at the same time of bacterial

3.6. LL-37 and CAMA moderately stimulate IL-6 and IL-8 release
from IB3-1 cells
We examined the effect of the two CAMPs on cytokine/chemokine secretion by exposing IB3-1 and A549 cells to a range of LL37 and CAMA concentrations of up to 50 mg/mL for LL-37
and 35 mg/mL for CAMA for 24 and 48 h, as these concentrations showed no cytotoxic effect on HLECs.
LL-37 and CAMA induced modest dose- and time-dependent IL6 and IL-8 release from IB3-1 cells (Fig. 5A). We observed signiﬁcantly greater IL-6 release following treatment with 25e50 mg/mL
LL-37 (P < 0.05) and 5e35 mg/mL CAMA after 24 and 48 h (P < 0.05)
than for untreated controls. We also observed signiﬁcantly greater
IL-8 release following treatment with 50 mg/mL LL-37 after 24 and
48 h (P < 0.05), 35 mg/mL CAMA after 24 h (P < 0.05), and 5e35 mg/
mL CAMA after 48 h (P < 0.05) than for untreated controls (Fig. 5A).
However, IL-6 and IL-8 levels in the supernatants were insigniﬁcant
relative to positive controls stimulated with Tumor necrosis factora (TNF-a) or LPS. We observed no signiﬁcant increase in PGE2 levels
following treatment of IB3-1 cells with either LL-37 or CAMA.
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Fig. 4. LDH-based cytotoxicity (percentages) of various concentrations of LL-37 and CAMA on: A. IB3-1 and B. A549 cell lines at 24 and 48 h incubation with LL-37. Results are
representative of the mean ± SD of at least three independent experiments.

neutrophils can be found in the sputum of CF patients during
infection with PAK. Among them, cathepsins K and S have been
shown to cleave LL-37 [35]. These proteases belong to the family of
cysteine-proteases which are insensitive to PMSF, a ﬁnding in
agreement with our results showing that LL-37 degradation by
supernatants from infected IB3-1 cells was not prevented by pretreatment of these supernatants by PMSF. This is also in agreement
with previous reports showing that bronchial epithelial cells from
CF patients produce higher levels of cathepsins compared to non CF
cells [36].
As mentioned above, it is possible that PA produces proteases,
such as PAE, capable of degrading LL-37 [37]. Based on our results,
there was no degradation of LL-37 in the presence of PAK alone but
only in the presence of IB3-1 cells infected with PAK. Thus, it is
likely that the interaction of bronchial epithelial cells with PA induces the production of proteases by the bacterial strain and/or
IB3-1 cells that may cleave LL-37.
It is also possible that LL-37 can bind to IB3-1, which may then
sequester this peptide, making it less available to direct bacterial
killing. In support of our hypothesis, we found that the amount of
LL-37 bound to the IB3-1 cells increased in a time-dependent
manner, whether these cells were infected or not with PAK. As
LL-37 is a strongly cationic peptide, it is possible that it binds to the
membranes of bronchial epithelial cells with high afﬁnity.
It could be argued that IB3-1 cells produce LL-37 during infection by PAK and that this endogenous LL-37 may interfere with the
quantiﬁcation of the exogenously added LL-37. We demonstrated
that LL-37 is not upregulated by IB3-1 cells even when stimulated
by vitamin D. Moreover, LL-37 mRNA expression by IB3-1 cells
infected with PAK and its mutant DExoS (known to be less virulent

administration or 30 min after than in the absence of host cells. This
suggests probable inactivation of these peptides via a number of
potential mechanisms, including degradation of the CAMPs by
proteases released by IB3-1 cells or by PA and/or inhibition of their
bactericidal effects by molecules that bind to CAMPs. Indeed, PA is
known to produce extracellular enzymes (P. aeruginosa elastase
(PAE), and alkaline protease (PAP)) in the early stages of infection,
which may contribute to inactive CAMPs and ensure their survival
in the host. Besides, PA can invade and survive within eukaryotic
cells [30,31], which may allow this bacterium to escape the bactericidal actions of CAMPs. Bacterial internalization has been clearly
documented for both epithelial [32] and phagocytic cells [33]
in vitro, as well as in infected mice [34].
We performed Western-blotting experiments to determine
whether degradation of LL-37 is the principal mechanism underlying the inhibition of its antibacterial action when administrated
30 min post-infection to IB3-1 cells. These experiments showed a
decrease in the amount of LL-37 in the supernatants from uninfected IB3-1 cells, which was further decreased in the supernatants
of infected IB3-1 cells. Interaction of IB3-1 cells with the PAK strain
appeared to induce a greater decrease in the peptide, possibly due
to the release of proteases by the IB3-1 cells or PAK. Our results also
showed that when supernatants from IB3-1 cells were pretreated
with the serine-protease inhibitor PMSF before addition of LL-37,
no changes were observed in the magnitude of LL-37 degradation
by these supernatants. This suggested that the apparent cleavage of
LL-37 by supernatants from PAK infected IB3-1 cells is probably not
due to the release by these cells of serine-proteases.
In addition, studies have shown that proteases (such as cathepsins) produced by human alveolar macrophages and
7
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Fig. 5. Assessment of cytokine and chemokine release upon stimulation of HLECs with various concentrations of LL-37 or CAMA for up to 48 h. Bar graphs show the amount of IL-6,
IL-8, and PGE2 secreted into the culture supernatants of: A. IB3-1 and B. A549 cell lines. The values represent the means ± SD of three independent experiments. *P < 0.05 for
stimulated vs unstimulated control cells. IB3-1 cells stimulated with LPS and TNF-a served as positive controls. LPS: lipopolysaccharide, TNF-a: tumor necrosis factor-a.

on the stimulus and inﬂammatory context [24]. We observed
signiﬁcantly enhanced IL-6 release upon treatment with LL-37 and
CAMA. However, IL-6 release was very weak relative to that
induced by the potent pro-inﬂammatory stimuli TNF-a and LPS.
These results suggest a role of LL-37-mediated IL-6 release in the
maintenance of the delicate inﬂammatory balance in the lungs, as
reported elsewhere [24,40], and, for the ﬁrst time, a similar role for
CAMA-mediated IL-6 release. IL-8 is best known for its leukocyte
chemotactic properties [25]. We observed a signiﬁcant increase in
the release of this chemokine upon LL-37 and CAMA treatment
(P < 0.05) relative to non-treated controls. However, IL-8 release
was very weak relative to that induced by the potent proinﬂammatory stimuli TNF-a and LPS, showing a non-proinﬂammatory effect of the tested concentrations of these peptides. PGE2, synthesized by many mammalian cells and tissues
throughout the body, has long been considered to be the principal

than the parental PAK) at MOI 1 and 5 were assessed by reverse
transcription polymerase chain reaction (RT-PCR). Our results
showed no LL-37 mRNA expression by IB3-1 cells infected or not
with PAK (data not shown).
Plus, we revealed that the doses of the two CAMPs used is this
study (50 mg/mL for LL-37 and 35 mg/mL for CAMA) were nontoxic for the two tested host cell lines for up to 48 h of treatment.
Our results conﬁrm the previously reported non-cytotoxicity of LL37 after 24 h of treatment [38] and demonstrate its noncytotoxicity on two types of host cells after 48 h of treatment
[39]. Furthermore, we showed the hybrid peptide CAMA to also be
non-toxic for two HLECs.
In addition, we showed that LL-37 and CAMA weakly stimulate
IL-6 cytokine and IL-8 chemokine release from IB3-1 cells. PGE2
release was not signiﬁcant for either cell type. In the lung, IL-6 can
act as a pro-inﬂammatory or anti-inﬂammatory agent, depending
8
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prostaglandin in acute inﬂammation. We observed no release of
PGE2 by LL-37-, and CAMA-treated HLECs, revealing no proinﬂammatory effect of the tested CAMPs. Overall, these results
suggest that these CAMPs could be potential drug candidates to
cure bacterial infection in clinical practice, as they show no
excessive pro-inﬂammatory effects on host cells but rather induce
the minimal inﬂammation crucial in the process of defense against
bacterial infections. Finally, the slight differences in terms of
interleukin and chemokine release by the two cell types tested in
this study suggest cell-type speciﬁcity [40].
Our results support the potential prophylactic use of LL-37 and
CAMA in the control of PA, an opportunistic bacterium known to
infect immune-deﬁcient or chronically ill patients. However, previously infected host cells may attenuate or even suppress the
bactericidal effects of CAMPs. The protection of CAMPs from such
inactivation is a perquisite step before proposing these compounds
for potential therapeutic use.

[13] Steiner H, Hultmark D, Engstrom A, Bennich H, Boman H. Sequence and
speciﬁty of two antibacterial proteins involved in insect immunity. Nature
1981;292:246e8.
[14] Pragman AA, Berger JP, Williams BJ. Understanding persistent bacterial lung
infections: clinical implications informed by the biology of the microbiota and
bioﬁlms. Clin Pulm Med 2016;23:57e66.
[15] Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded
resistance mechanisms. Clin Microbiol Rev 2009;22:582e610.
[16] Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic ﬁbrosis.
Antimicrob Agents Chemother 2002;15:194e222.
[17] Zhang L, Parente J, Harris SM, Woods DE, Hancock REW, Falla TJ. Antimicrobial peptide therapeutics for cystic ﬁbrosis. Antimicrob Agents Chemother
2005;49:2921e7.
https://doi.org/10.1128/AAC.49.7.29212927.2005.
[18] Moser C, Gennip MVAN, Bjarnsholt T, Jensen PØ, Lee B, Hougen HP, et al.
Novel experimental Pseudomonas aeruginosa lung infection model
mimicking long-term host e pathogen interactions in cystic ﬁbrosis. APMIS
2009;2:95e107.
[19] Geitani R, Moubareck CA, Touqui L, Sarkis DK. Cationic antimicrobial peptides
: alternatives and/or adjuvants to antibiotics active against methicillinresistant Staphylococcus aureus and multidrug-resistant Pseudomonas aeruginosa. BMC Microbiol 2019;19:1e12.
[20] Pernet E, Guillemot L, Burgel P-R, Martin C, Lambeau G, Sermet-Gaudelus I,
et al. Pseudomonas aeruginosa eradicates Staphylococcus aureus by manipulating the host immunity. Nat Commun 2014;5:5105. https://doi.org/
10.1038/ncomms6105.
[21] National Committee for Clinical Laboratory standards. Approved Standards
M7-A3. Methods for dilution susceptibility tests for bacteria that grow aerobically. 1993.
[22] Giacometti A, Cirioni O, Barchiesi F, Del Prete MS, Fortuna M, Caselli F, et al.
In vitro susceptibility tests for cationic peptides: comparison of broth
microdilution methods for bacteria that grow aerobically. Antimicrob Agents
Chemother 2000;44:1694e6.
[23] Field D, Connor RO, Cotter PD, Ross RP, Hill C. In vitro activities of nisin and
nisin derivatives alone and in combination with antibiotics against Staphylococcus bioﬁlms. Front Microbiol 2016;7 April:1e11.
[24] Pistolic J, Li Y, Yu J, Filewod CJ. Host defence peptide LL-37 induces IL-6
expression in human bronchial epithelial cells by activation of the NF- MB
signaling pathway. J Innate Immun 2009;1:254e67.
[25] Mohamed F Ben, Garcia-verdugo I, Medina M, Balloy V. A crucial role of
ﬂagellin in the induction of airway mucus production by Pseudomonas aeruginosa. PLoS One 2012;7.
[26] Giacometti A, Cirioni O, Barchiesi F, Simona M, Prete D, Scalise G. Antimicrobial activity of polycationic peptides. Peptides 1999;20:1265e73.
[27] Dosler S, Mataraci E. In vitro pharmacokinetics of antimicrobial cationic
peptides alone and in combination with antibiotics against methicillin resistant Staphylococcus aureus bioﬁlms. Peptides 2013;49:53e8. https://doi.org/
10.1016/j.peptides.2013.08.008.
[28] Lai Y, Gallo RL. AMPed up immunity : how antimicrobial peptides have
multiple roles in immune defense. Trends Immunol 2009;30(February):
131e41.
[29] Shaykhiev R, Beißwenger C, Ka K, Senske J, Damm T, Bals R, et al. Human
endogenous antibiotic LL-37 stimulates airway epithelial cell proliferation and
wound closure. Am J Physiol Lung Cell Mol Physiol 2015;289:842e8.
[30] Bernut A, Belon C, Soscia C, Bleves S. Intracellular phase for an extracellular
bacterial pathogen : MgtC shows the way. Microb cell 2015;2:353e5.
[31] Buyck JM, Tulkens PM, Bambeke F Van. Pharmacodynamic evaluation of the
intracellular activity of antibiotics towards Pseudomonas aeruginosa PAO1 in
a model of THP-1 human monocytes. Antimicrob Agents Chemother 2013;57:
2310e8.
[32] Garcia-medina R, Dunne WM, Singh PK, Brody SL. Pseudomonas aeruginosa
acquires bioﬁlm-like properties within airway epithelial cells. Infect Imm
2005;73:8298e305.
[33] Porto P Del, Cifani N, Guarnieri S, Gino E, Domenico D, Mariggio MA, et al.
Dysfunctional CFTR alters the bactericidal activity of human macrophages
against Pseudomonas aeruginosa. PLoS One 2011;6.
[34] Schmiedl A, Kerber-momot T. Bacterial distribution in lung parenchyma early
after pulmonary infection with Pseudomonas aeruginosa. Cell Tissue Res
2010;342:67e73.
[35] Andrault P-M, Samsonov S, Weber G, Coquet L, Nazmi K, Bolsher J, et al.
Antimicrobial peptide LL-37 is both a substrate of cathepsins S and K and a
selective inhibitor of cathepsin L. Biochemistry 2015;54:2785e98.
[36] Mcnally P, Mcauley DF, Oglesby IK, Wohlford-lenane CL, Bartlett JA, Scott CJ,
et al. miR-31 dysregulation in cystic ﬁbrosis airways contributes to increased
pulmonary cathepsin S production. Am J Respir Crit Care Med Vol 2014;190:
165e74.
[37] Wretlind B, Pavlovskis OR. Pseudomonas aeruginosa elastase and its role in
Pseudomonas infections. Clin. Infect. Dis. 5, S998eS1004 (1983. Clin Infect Dis
1983;5:S998e1004.
[38] Lau YE, Rozek A, Scott MG, Goosney DL, Davidson DJ, Hancock REW, et al.
Interaction and cellular localization of the human host defense peptide LL-37
with lung epithelial cells. Infect Immun 2005;73:583e91.

Declaration of competing interest
The authors have no conﬂicts of interest to disclose.
Acknowledgements
The authors thank “Fondation Air Liquide” (Grant: S-CM19006)
and Association «Les Motards du Viaduc de Millau » for funding the
project. The authors thank Mrs Nora Touqui, a professional
specialized in editing scientiﬁc papers.
Appendix A. Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.micinf.2021.104928.
References
[1] Nigam A, Gupta D, Sharma A. Treatment of infectious disease: beyond antibiotics. Microbiol Res 2014;169:643e51.
[2] Aloush V, Navon-venezia S, Seigman-igra Y, Cabili S, Carmeli Y. Multidrugresistant Pseudomonas aeruginosa : risk factors and clinical impact. Antimicrob Agents Chemother 2006;50:43e8.
[3] da Costa JP, Cova M, Ferreira R, Vitorino R. Antimicrobial peptides: an alternative for innovative medicines? Appl Microbiol Biotechnol 2015;99:
2023e40.
€rn C. Antimicrobial peptides : an
[4] Mahlapuu M, Håkansson J, Ringstad L, Bjo
emerging category of therapeutic agents. Front Cell Infect Microbiol 2016;6.
n LM. Antimicrobial
[5] Guaní-Guerra E, Santos-Mendoza T, Lugo-Reyes SO, Tera
peptides: general overview and clinical implications in human health and
disease.
Clin
Immunol
2009;135:1e11.
https://doi.org/10.1016/
j.clim.2009.12.004.
[6] Geitani R, Moubareck CA, Xu Z, Sarkis DK. Expression and roles of antimicrobial peptides in innate defense of airway mucosa : potential implication in
cystic ﬁbrosis. Front Immunol 2020;11 June:1e11.
[7] Otvos Jr L. Immunomodulatory effects of anti-microbial peptides. Acta
Microbiol Immunol Hung 2016;63:257e77. https://doi.org/10.1556/
030.63.2016.005.
[8] De Smet K, Contreras R. Human antimicrobial peptides: defensins, cathelicidins and histatins. Biotechnol Lett 2005;27:1337e47.
[9] Hiemstra PS, Amatngalim GD, Does AM Van Der, Taube C. Antimicrobial
peptides and innate lung defenses role in infectious and noninfectious lung
diseases and therapeutic. Chest 2019;149:545e51. https://doi.org/10.1378/
chest.15-1353.
[10] Pasupuleti M, Schmidtchen A, Malmsten M. Antimicrobial peptides : key
components of the innate immune system. Crit Rev Biotechnol 2012;32:
143e71.
[11] Xhindoli D, Pacor S, Benincasa M, Scocchi M, Gennaro R, Tossi A. The human
cathelicidin LL-37 d a pore-forming antibacterial peptide and host-cell
modulator. Biochim Biophys Acta 2016;1858:546e66. https://doi.org/
10.1016/j.bbamem.2015.11.003.
[12] Mataraci E, Dosler S. In vitro activities of antibiotics and antimicrobial cationic
peptides alone and in combination against methicillin-resistant Staphylococcus aureus bioﬁlms. Antimicrob Agents Chemother 2012;56:6366e71.

9

R. Geitani, C.A. Moubareck, F. Costes et al.

Microbes and Infection 24 (2022) 104928
receptor and c-jun N-terminal and extracellular signal-regulated kinases in
cyclooxygenase-2 and prostaglandin E 2 induction by LL-37. J Immun Innate
Res 2013;5:72e83.

[39] Johansson J, Gudmundsson GH, Rottenberg E, Berndt KD, Agerberth B.
Conformation-dependent antibacterial activity of the naturally occurring
human peptide LL-37 *. J Biol Chem 1998;273:3718e24.
[40] Chotjumlong P, Bolscher JG, Nazmi K, Reutrakul V, Supanchart C,
Krisanaprakornkit WBS. Immunity involvement of the P2X 7 purinergic

10

